Category Archives: FDA


Direct to Consumer Genetic Testing: Risks and Opportunities






Accurate genetic testing stands to transform modern medicine by offering effective, personalized treatment. Last week, the U.S. Food and Drug Administration (FDA) authorized marketing of the first direct-to-consumer (DTC) genetic health risk (GHR) tests. Individuals in the US can now purchase DTC tests and gain potentially useful information on their genetic predisposition to 10 diseases […]

Read More

Posted in FDA, Non-communicable diseases;


FEDERAL TOBACCO CONTROL DURING THE TRUMP YEARS – AND TOBACCO PRODUCT INSERTS






Although the federal Tobacco Control Act gives the U.S. Food and Drug Agency extensive authorities to regulate tobacco products and their marketing, labeling, and sale, the Trump Administration’s new pro-business, anti-regulation approach might put some serious obstacles in the way of any significant new FDA regulations to reduce the massive amounts of tobacco use and […]

Read More

Posted in FDA, Tobacco; Tagged: , , , , , , , , , , .


Carfentanil






In an international game of Whac-A-Mol, this week China announced that it would be adding four lethal heroin-like narcotics to a list of controlled substances to help combat the growing opioid epidemic in America. The primary target of the ban is Carfentanil, one of the latest and deadliest synthetic opioids to show up in the […]

Read More

Posted in FDA, Global Health, Health reform, Trade, Uncategorized;


Obama signs $6.3 billion Cures Act – But Does it Do More Harm than Good?






On December 13th, President Obama signed the 21st Century Cures Act into law. This law provides $6.3 billion for cancer cure research, and to address the growing opioid drug abuse epidemic. The Act also allows for a more streamlined approval process for the FDA to bring new drugs and medical devices to the market. While […]

Read More

Posted in FDA, Health reform, Uncategorized; Tagged: , .


The Exorbitant Pricing of Pharmaceuticals is in the News. Again.






This week the pharmaceutical pricing discussion centers on Mylan, and its 548% boost in the price of EpiPens. The press coverage and industry promises are a familiar scene: a large drug company buys a well-established medication or technology, and then raises the price. There is outrage, there are statements of promises and remedies, and then […]

Read More

Posted in FDA, Global Health, Uncategorized;


Archives

Stay Informed

Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute

Or sign up for our RSS Feed

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.